| sertraline / Generic mfg. |
ChiCTR2200066412: Efficacy and safety of mood stabilizers versus antidepressants for youth depression: a randomised, open-label, pilot study |
|
|
| Not yet recruiting | N/A | 40 | | Lamotrigine and Lithium Carbonate Sustained-release ;Sertraline | Wuhan Mental Health Center; Wuhan Mental Health Center, Pivot Subjects in Wuhan Mental Health Center | Depression | | | | |
ChiCTR2300068054: Immunomodulation and brain spatial transcriptional profiling in mild to moderate depression treated with the acupuncture method of consolidating the essence and regulating the mind |
|
|
| Not yet recruiting | N/A | 48 | | No processing ;Oral sertraline ;oral sertraline + the acupuncture method of consolidating the essence and regulating the mind ;oral sertraline + sham needle | Shenzhen Baoan District Hospital of Traditional Chinese Medicine; Shenzhen Baoan District Hospital of Traditional Chinese Medicine, Shenzhen Bao'an TCM Development Foundation | Depression | | | | |
ChiCTR2300071004: Clinical application of a new technique of esketamine rapid antidepressant treatment in adolescents and maternal cesarean section population |
|
|
| Not yet recruiting | N/A | 374 | | Esketamine was administered as a 0.25 mg/kg injection diluted to 50 m L intravenous drip over 40 minutes with saline injection. For all subjects in the esketamine and control groups who were currently taking SSRI/SNRI antidepressants and were at an effective dose, the original treatment was maintained; if not at an effective dose then the dose was rapidly increased to an effective dose after enrollment. Patients not currently taking medication were started on sertraline hydrochloride at a dose of 50-200 mg, and the medication was increased to the effective dose with esketamine IV treatment. All patients maintained the same drug type and dose during the follow-up period after IV treatment. ;For all subjects in the esketamine and control groups who were currently taking SSRI/SNRI antidepressants and were at an effective dose, the original treatment was maintained; if not at an effective dose, it was rapidly increased to an effective dose after enrollment. Patients not currently taking medication were started on sertraline hydrochloride at a dose of 50-200 mg. ;In the esketamine group, esketamine (0.25 mg/kg diluted in 10 mL of 0.9% saline) was administered 10 minutes after delivery of the fetus by cesarean section. A trained investigator recorded the vital signs and adverse effects during the procedure. For the postoperative analgesic session esketamine group, sufentanil (100 ug), esketamine (80 mg) and palonosetron hydrochloride (0.25 mg) were dissolved in 100 ml of saline using a patient-controlled intravenous analgesia (PCIA) device (infusion rate: 2 mL/hour; pill dose: 2 mL, lock time: 8 min) ;No esketamine was given to the control group. A trained investigator recorded vital signs and adverse reactions during the procedure. The postoperative analgesic session was performed with sufentanil (100 ug), palonosetron hydrochloride (0.25 mg) dissolved in 100 ml of saline, using a patient-controlled intravenous analgesia (PCIA) device (infusion rate: 2 mL/hour; pill dose: 2 ml, lock time: 8 minutes). | Beijing Chaoyang Hospital; Beijing Chaoyang Hospital, In-Hospital Funding | Depression | | | | |
ChiCTR2200064527: Multimodal Brain Magnetic Resonance Study on electroconvulsive therapy for adolescent depression with suicide |
|
|
| Recruiting | N/A | 200 | | none ;pharmcotherapy (sertraline) ;pharmcotherapy (sertraline) + ECT ;psychotherapy (sertraline)/physical therapy/psychotherapy (not included in statistics) | The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, National Natural Science Foundation of China (No: 81971286) | depression | | | | |
ANTILOP, NCT04147000: Pharmacokinetics and Pharmacodynamics of Oral Sertraline Before and After Bariatric Surgery |
|
|
| Terminated | N/A | 3 | Europe | | Linkoeping University, Örebro University, Sweden | Overweight, Depression, Anxiety Disorders | 11/23 | 11/23 | | |
NCT05683223: Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety |
|
|
| Recruiting | N/A | 240 | US | Group CBT for Social Anxiety Disorder, SAD Group, Sertraline, Non-responder Meds, Individual CBT for Social Anxiety Disorder, Non-responder CBT | Boston University Charles River Campus, Massachusetts Institute of Technology, Mclean Hospital, National Institute of Mental Health (NIMH) | Social Anxiety Disorder | 12/26 | 06/27 | | |
ChiCTR2300073584: A double-blind, randomized, placebo controlled study of the efficacy of repeated transcranial magnetic stimulation (rTMS) combined with sertraline in the treatment of depression |
|
|
| Not yet recruiting | N/A | 230 | | Sertraline ;Sertraline combined with rTMS | West China Hospital of Sichuan University; West China Hospital of Sichuan University, West China Hospital of Sichuan University | major depressive disorder | | | | |
